Market revenue in 2023 | USD 646.3 million |
Market revenue in 2030 | USD 1,613.7 million |
Growth rate | 14% (CAGR from 2023 to 2030) |
Largest segment | Rna-based therapies |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, RNA-based Therapies |
Key market players worldwide | Catalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nucleic acid therapeutics cdmo market will help companies and investors design strategic landscapes.
Rna-based therapies was the largest segment with a revenue share of 65.79% in 2023. Horizon Databook has segmented the Germany nucleic acid therapeutics cdmo market based on gene therapy, rna-based therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical & biotechnology industry in Germany is one of the world’s largest industries. The country is one of the major locations for CDMO services along with the UK in Europe. Technological advancements and quality clinical resources are some of the primary factors expected to propel market growth over the forecast period.
Moreover, government initiatives for clinical research activities have accelerated the growth of nucleic acid therapeutics CDMO market. Furthermore, according to GTAI, the country provides the appropriate environment for the development & production of research-intensive, high-grade products.
Likewise, the demand for the development of nucleic acid therapeutics in CDMOs has led to shifts in the pharmaceutical industry landscape in the past few years. Numerous companies have moved their focus toward the development and production of nucleic acid therapeutics with the support of CDMOs.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany nucleic acid therapeutics cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Germany nucleic acid therapeutics cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account